HALO logo
halo search icon
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc.
ZNTL · NAS

Zentalis Pharmaceuticals, Inc.

US$3.71

Price Arrow0.17 (4.80%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig CandleHALO AllHammer BullishHammer Bullish (Realtime)
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Zentalis Pharmaceuticals, Inc. Overview

ZNTL Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Neutral

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About ZNTL

icon

Telephone

1.858.263.4333

icon

Address

Suite 200, 10275 Science Center Drive, San Diego, CA 92121

Description

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

ZNTL Price Chart

Key Stats

Market Cap

US$252.00M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.13 - 6.95

Trade Value (12mth)

US$970,039.00

1 week

-12.59%

1 month

-11.28%

YTD

158.39%

1 year

192.56%

All time high

87.19

Key Fundamentals

EPS 3 yr Growth

-57.40%

EBITDA Margin

0.00%

Operating Cashflow

-$125m

Free Cash Flow Return

-39.80%

ROIC

-43.60%

Interest Coverage

0.00

Quick Ratio

6.90

Other Data

Shares Outstanding (Fully Diluted)

70m

HALO Sector

Healthcare

Next Company Report Date

03-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

ZNTL Announcements

Latest Announcements

DateAnnouncements
13 May 26
13 May 26
13 May 26
13 May 26
13 May 26

ZNTL Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-4.47-2.33-1.91locklocklock
EPS (Fully Diluted)
$locklocklocklock-4.47-2.33-1.91locklocklock
Growth
%locklocklocklock0.347.818.3locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Zentalis Pharmaceuticals, Inc. (ZNTL:NAS)?
Halo FAQ
The current share price of Zentalis Pharmaceuticals, Inc. (ZNTL:NAS) is USD$3.71.
What is the 52-week high share price for Zentalis Pharmaceuticals, Inc. (ZNTL:NAS)?
Halo FAQ
The 52-week high share price for Zentalis Pharmaceuticals, Inc. (ZNTL:NAS) is USD$6.95.
What is the 52-week low share price for Zentalis Pharmaceuticals, Inc. (ZNTL:NAS)?
Halo FAQ
The 52-week low share price for Zentalis Pharmaceuticals, Inc. (ZNTL:NAS) is USD$1.13.
What is the dividend yield for Zentalis Pharmaceuticals, Inc. (ZNTL:NAS)?
Halo FAQ
Zentalis Pharmaceuticals, Inc. (ZNTL:NAS) does not pay a dividend.
What was Zentalis Pharmaceuticals, Inc. (ZNTL:NAS) last dividend payment?
Halo FAQ
Zentalis Pharmaceuticals, Inc. (ZNTL:NAS) does not pay a dividend.
What is the franking level for Zentalis Pharmaceuticals, Inc. (ZNTL:NAS)?
Halo FAQ
Zentalis Pharmaceuticals, Inc. (ZNTL:NAS) has a franking level of 0.00%.
In which sector is Zentalis Pharmaceuticals, Inc. (ZNTL:NAS) classified?
Halo FAQ
Zentalis Pharmaceuticals, Inc. (ZNTL:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.